Abstract:Immunotherapy (IO), especially a subgroup called immune checkpoint inhibitors (ICIs) has revolutionized the treatment of a variety of cancers in past few years. ICIs include anti-PD-1 & anti-PD-L1 antibodies, as well as CTLA-4 inhibitors. Clinical trials showed that ~15% to 40% of cancer patients (sometime more) respond to ICIs (1,2). Time for response can be longer than those with traditional chemotherapy. Hence IOs may not be very appropriate for patients who require immediate cytoreduction for symptom relief or those near end-of-life. During initial phase of IO treatment, new lesions can occur as a result of inflammatory process, but they subsequent regress. This is called “pseudoprogression”. It occurs in ≤5% of cases (3). Some patients who do not meet the criteria of objective response on traditional RECIST criteria may achieve prolonged periods of stable disease that are clinically significant. This leads to the proposal of using iRECIST criteria in IO studies. On the other hand, ~10% (4) of patient may exhibit hyperprogression phenomenon (doubling of tumor growth rate within ≤12 wks after start of treatment). Some researchers suggested that hyperprogression might be more commonly seen in elderlies, and may be associated with certain gene mutations (2,4). If hyperprogression occurs, prognosis is usually poor. Switching to alternative systemic therapy or best supportive care may be considered if appropriate. Despite promising results published, most of the patients succumb after treatment. Only a minority of patient achieved durable response and have prolong survival. The majority of irAEs occur within first 4 months of ICI treatment, but irAEs can occur months after completion of IO (5). Some irAEs are devastating, long lasting and fatal. Severe flare up of psoriasis, pneumonitis, colitis, cardiac toxicities, neurological irAEs and graft rejection after transplant have been reported. In general, the overall toxicities leading to discontinuation treatment due to irAEs are higher with CTLA-4 inhibitors like ipilimumab than anti-PD1 therapy using nivolumab or pembrolizumab (6). Immune related colitis/gastrointestinal irAEs & hypophysitis may be more common in CTLA4 inhibitors. On the other hand, thyroid related irAEs, vitiligo, pneumonitis ± graft rejection may be more frequent in anti-PD1 therapy (2). The safety data for PD-L1 inhibitors are still maturing. Details of grading of various irAEs & their managements have been published (2,7) and will not be discussed in details here. Patients who develop grade 3–4 irAEs need prompt recognition, treatment and close monitoring of response to systemic steroid ± other immunomodulatory agent(s). Tailing down of steroid should be slow, at least over 4–6 wks to avoid recurrence of irAEs. At present, some clinical trials are exploring the role of combinations IOs with other IOs, novel agents, chemotherapy and radiotherapy. Higher treatment related toxicities are expected in combination treatments. Median progression-free survival (PFS) & median overall survival (OS) might be good enough outcome Editorial

Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1

Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity

Immune Checkpoints as Therapeutic Targets in Autoimmunity

Immunotherapy for metastatic cancer patients: the current status, limitations, obstacles and future directions.

Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition

Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review

Therapeutic importance, general and endocrine adverse effects of immune checkpoint inhibitors I: mechanism of action and therapeutic use

Time to dissect the autoimmune etiology of cancer antibody immunotherapy

Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer

Advances of immune-checkpoint inhibition of CTLA-4 in pancreatic cancer

Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations

A comprehensive review of immune checkpoint inhibitors for cancer treatment

Immune checkpoint inhibitors: breakthroughs in cancer treatment

Addressing the Elephant in the Immunotherapy Room: Effector T-Cell Priming versus Depletion of Regulatory T-Cells by Anti-CTLA-4 Therapy

[Development of immune checkpoint inhibitors]

Novel Combination Strategies to Enhance Immune Checkpoint Inhibition in Cancer Immunotherapy: A Narrative Review

Soluble CTLA-4 Mutants Ameliorate Immune-Related Adverse Events but Preserve Efficacy of CTLA-4– and PD-1–targeted Immunotherapy

Facts and Hopes in Prediction, Diagnosis, and Treatment of Immune-Related Adverse Events

Toxicity in the era of immune checkpoint inhibitor therapy

Combined anti‐PD‐1 and anti‐CTLA‐4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action